{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:21Z","timestamp":1792806201017,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20306"],"award-info":[{"award-number":["DB-2020C2-20306"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113503","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:38:15Z","timestamp":1786981095000},"page":"113503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3857-9445","authenticated-orcid":false,"given":"Stacey M.","family":"Sklepinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-3622","authenticated-orcid":false,"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6841-7706","authenticated-orcid":false,"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3664-127X","authenticated-orcid":false,"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113503_b0005","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.diabres.2026.113503_b0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-022-01344-7","article-title":"Use of antihyperglycemic drugs and risk of cancer in patients with diabetes","volume":"25","author":"S\u00f8ndergaard","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.diabres.2026.113503_b0015","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113503_b0020","doi-asserted-by":"crossref","unstructured":"Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. Published online November 29, 2023. doi:10.1111\/dom.15382.","DOI":"10.1111\/dom.15382"},{"issue":"3","key":"10.1016\/j.diabres.2026.113503_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA use and thyroid cancer risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.diabres.2026.113503_b0030","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.diabres.2026.113503_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1060028015610123","article-title":"Dipeptidyl peptidase-4 inhibitor-associated pancreatic carcinoma: a review of the FAERS database","volume":"50","author":"Nagel","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.diabres.2026.113503_b0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pds.5550","article-title":"A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer","volume":"32","author":"Hidayat","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.diabres.2026.113503_b0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113503_b0050","doi-asserted-by":"crossref","unstructured":"Ko A, Chang YC, Bahar F, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Ann Intern Med; 2025. ANNALS-25-02237. Published online December 9. doi:10.7326\/ANNALS-25-02237.","DOI":"10.7326\/ANNALS-25-02237"},{"key":"10.1016\/j.diabres.2026.113503_b0055","doi-asserted-by":"crossref","unstructured":"Mao X, Zhang X, Henry L, et al. Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study. JNCI: J Natl Cancer Inst; 2025. Published online July 9. doi:10.1093\/jnci\/djaf163.","DOI":"10.1093\/jnci\/djaf163"},{"key":"10.1016\/j.diabres.2026.113503_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/cancers17010078","article-title":"Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients","volume":"17(1)","author":"Levy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.diabres.2026.113503_b0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.diabres.2026.113503_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"issue":"8","key":"10.1016\/j.diabres.2026.113503_b0075","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113503_b0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.diabres.2026.113503_b0085","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"10.1016\/j.diabres.2026.113503_b0090","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2014 viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113503_b0095","unstructured":"Clinical Classifications Software Refined (CCSR). Healthcare Cost and Utilization Project (HCUP). Published online November 19, 2025. https:\/\/hcup-us.ahrq.gov\/toolssoftware\/ccsr\/ccs_refined.jsp [accessed June 3, 2026]."},{"key":"10.1016\/j.diabres.2026.113503_b0100","unstructured":"Polley, E, LeDell, E, Kennedy, C, Lendle, S, van der Laan, M. SuperLearner: Super Learner Prediction. Published online 2021. https:\/\/CRAN.R-project.org\/package=SuperLearner [accessed October 4, 2023]."},{"key":"10.1016\/j.diabres.2026.113503_b0105","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113503_b0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"issue":"19","key":"10.1016\/j.diabres.2026.113503_b0115","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.diabres.2026.113503_b0120","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113503_b0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2026.113503_b0130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"17","key":"10.1016\/j.diabres.2026.113503_b0135","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"issue":"539","key":"10.1016\/j.diabres.2026.113503_b0140","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1080\/01621459.2020.1864382","article-title":"Sensitivity analysis via the proportion of unmeasured confounding","volume":"117","author":"Bonvini","year":"2022","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.diabres.2026.113503_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.0006-341X.2001.00103.x","article-title":"Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring","volume":"57","author":"Rotnitzky","year":"2001","journal-title":"Biometrics"},{"issue":"23","key":"10.1016\/j.diabres.2026.113503_b0150","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023","volume":"331","author":"Lee","year":"2024","journal-title":"J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.diabres.2026.113503_b0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.diabres.2026.113503_b0160","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK clinical practice research datalink","volume":"355","author":"Hicks","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113503_b0165","article-title":"The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study","volume":"16(9)","author":"Ayoub","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.diabres.2026.113503_b0170","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.3390\/cancers16183224","article-title":"Risk of esophageal and gastric cancer in patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs): a national analysis","volume":"16","author":"Ayoub","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.diabres.2026.113503_b0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.diabres.2026.113503_b0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.diabres.2026.113503_b0185","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/dom.15038","article-title":"Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon\u2010like peptide\u20101 receptor agonist: a retrospective analysis of the diabetes prospective follow\u2010up registry","volume":"25","author":"Jung","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:18:07Z","timestamp":1792804687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726004237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0168822726004237"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113503","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113503"}}